$498.86
At close: May 2 EDT
$503.10
4.240.85%
Pre-Market: 5:33 AM EDT
Comments
Loading...
Vertex Pharmaceuticals Insider Trading Activity | NASDAQ:VRTX | Benzinga
Track the latest Vertex Pharmaceuticals insider trading activity. Stay informed on recent buys, sells, and market impact for Vertex Pharmaceuticals stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Vertex Pharmaceuticals Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
- On February 24, 2025, DAVID ALTSHULER, the company's EVP, CHIEF SCIENTIFIC OFFICER sold 1.11K shares for $480 each.
- On February 19, 2025, Kristen Ambrose, the company's SVP & CHIEF ACCOUNTING OFFICER sold 1.24K shares for $458.9 each.
- On February 26, 2025, Kristen Ambrose, the company's SVP & CHIEF ACCOUNTING OFFICER sold 1.71K shares for $482.08 each.
Ownership Statistics for Vertex Pharmaceuticals Inc
Shares Outstanding
256.790M
Insider Shares Owned
2.498M
Insider Percentage Owned
0.97%
Institutional Shares Held
220.410M
Institutional Percentage Held
85.8%
| Mar 17, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $510.00 | -$1.65M | SELL | -12.19% | 23.28K | Mar 13 | View |
| Mar 12, 2025 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.30K | $500.00 | -$1.65M | SELL | -6.00% | 51.67K | Mar 10 | View |
| Mar 12, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -3.24K | $499.99 | -$1.62M | SELL | -5.95% | 51.24K | Mar 10 | View |
| Mar 12, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $500.00 | -$1.62M | SELL | -10.86% | 26.51K | Mar 10 | View |
| Mar 06, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -4.06K | $485.49 | -$1.97M | SELL | -6.93% | 54.48K | Mar 04 | View |
| Mar 05, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $490.00 | -$1.58M | SELL | -9.80% | 29.74K | Mar 03 | View |
| Feb 28, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -5.49K | $479.20 | -$2.63M | SELL | -8.58% | 58.54K | Feb 26 - Feb 27 | View |
| Feb 28, 2025 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -5.13K | $477.41 | -$2.45M | SELL | -20.96% | 19.35K | Feb 26 - Feb 27 | View |
| Feb 28, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -7.23K | $479.68 | -$3.47M | SELL | -17.98% | 32.97K | Feb 26 - Feb 27 | View |
| Feb 26, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $483.05 | -$1.77M | SELL | -5.41% | 64.03K | Feb 24 - Feb 25 | View |
| Feb 26, 2025 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -3.42K | $482.08 | -$1.65M | SELL | -12.27% | 24.48K | Feb 24 - Feb 25 | View |
| Feb 26, 2025 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $482.08 | -$825.32K | SELL | -15.85% | 9.09K | Feb 24 - Feb 25 | View |
| Feb 26, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -4.82K | $482.87 | -$2.33M | SELL | -10.70% | 40.20K | Feb 24 - Feb 25 | View |
| Feb 24, 2025 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -1.11K | $480.00 | -$533.28K | SELL | -2.41% | 45.02K | Feb 20 | View |
| Feb 19, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.54K | $462.65 | -$1.17M | SELL | -3.61% | 67.69K | Feb 14 - Feb 18 | View |
| Feb 19, 2025 | Jonathan Biller | EVP AND CHIEF LEGAL OFFICER | -3.16K | $459.06 | -$1.45M | SELL | -15.22% | 17.61K | Feb 14 - Feb 18 | View |
| Feb 19, 2025 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.24K | $458.90 | -$566.74K | SELL | -10.26% | 10.80K | Feb 14 - Feb 18 | View |
| Feb 12, 2025 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.45K | $466.95 | -$1.15M | SELL | -3.69% | 64.02K | Feb 10 - Feb 11 | View |
| Feb 12, 2025 | Jonathan Biller | EVP AND CHIEF LEGAL OFFICER | -5.07K | $462.48 | -$2.34M | SELL | -23.67% | 16.33K | Feb 10 - Feb 11 | View |
| Feb 12, 2025 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -2.62K | $462.55 | -$1.21M | SELL | -10.15% | 23.23K | Feb 10 - Feb 11 | View |
| Feb 12, 2025 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.97K | $462.28 | -$909.30K | SELL | -16.50% | 9.95K | Feb 10 - Feb 11 | View |
| Nov 19, 2024 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -15.00 | $478.56 | -$7.18K | SELL | -0.06% | 25.81K | Nov 15 | View |
| Nov 13, 2024 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $518.27 | -$1.55M | SELL | -6.36% | 44.14K | Nov 11 | View |
| Nov 12, 2024 | Reshma Kewalramani | CEO & PRESIDENT | -15.20K | $515.00 | -$7.83M | SELL | -16.71% | 75.77K | Nov 08 | View |
| Oct 03, 2024 | Jonathan Biller | EVP AND CHIEF LEGAL OFFICER | -1.63K | $463.66 | -$755.31K | SELL | -8.91% | 16.65K | Oct 01 - Oct 02 | View |
| Sep 04, 2024 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -3.78K | $499.00 | -$1.89M | SELL | -26.61% | 10.43K | Aug 30 | View |
| Sep 04, 2024 | Sangeeta Bhatia | DIRECTOR | 0.00 | $326.37 | -$224.33K | SELL-OPTIONS | 0.00% | 4.43K | Aug 30 | View |
| Aug 12, 2024 | Sangeeta Bhatia | DIRECTOR | 0.00 | $309.51 | -$405.11K | SELL-OPTIONS | 0.00% | 4.43K | Aug 08 | View |
| Aug 08, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $476.75 | -$1.09M | SELL | -8.93% | 23.26K | Aug 07 | View |
| Aug 02, 2024 | BRUCE SACHS | DIRECTOR | 0.00 | $316.86 | -$2.02M | SELL-OPTIONS | 0.00% | 40.00K | Aug 01 | View |
| Aug 01, 2024 | Reshma Kewalramani | CEO & PRESIDENT | -15.20K | $505.00 | -$7.68M | SELL | -14.32% | 90.97K | Jul 30 | View |
| Jul 25, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $488.46 | -$1.11M | SELL | -8.20% | 25.54K | Jul 24 | View |
| Jul 24, 2024 | Reshma Kewalramani | CEO & PRESIDENT | -15.20K | $497.00 | -$7.56M | SELL | -12.52% | 106.17K | Jul 22 | View |
| Jul 12, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $487.34 | -$1.11M | SELL | -7.58% | 27.82K | Jul 10 | View |
| Jun 28, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $471.72 | -$1.08M | SELL | -7.04% | 30.10K | Jun 26 | View |
| Jun 13, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $478.00 | -$1.09M | SELL | -6.58% | 32.38K | Jun 12 | View |
| Jun 13, 2024 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -14.11K | $479.91 | -$6.77M | SELL | -46.91% | 15.97K | Jun 11 - Jun 12 | View |
| Jun 05, 2024 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.25K | $460.00 | -$1.50M | SELL | -6.45% | 47.14K | Jun 03 | View |
| Jun 05, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.17K | $460.00 | -$1.00M | SELL | -4.24% | 49.10K | Jun 03 | View |
| Jun 03, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -4.60K | $441.99 | -$2.03M | SELL | -8.23% | 51.27K | May 30 - May 31 | View |
| May 31, 2024 | Carmen Bozic | EVP AND CMO | -2.28K | $445.56 | -$1.02M | SELL | -6.17% | 34.66K | May 29 | View |
| May 30, 2024 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.25K | $454.79 | -$1.48M | SELL | -6.06% | 50.39K | May 28 | View |
| May 29, 2024 | Reshma Kewalramani | CEO & PRESIDENT | 0.00 | $322.26 | -$421.72K | SELL-OPTIONS | 0.00% | 121.37K | May 24 | View |
| May 24, 2024 | BRUCE SACHS | DIRECTOR | 0.00 | $270.75 | -$2.51M | SELL-OPTIONS | 0.00% | 40.00K | May 22 | View |
| May 22, 2024 | Reshma Kewalramani | CEO & PRESIDENT | -15.20K | $447.00 | -$6.80M | SELL | -11.13% | 121.37K | May 20 | View |
| May 17, 2024 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -32.00 | $430.93 | -$13.79K | SELL | -0.06% | 56.21K | May 15 | View |
| May 17, 2024 | Stuart Arbuckle | EVP, COO | -69.00 | $430.93 | -$29.73K | SELL | -0.14% | 49.83K | May 15 | View |
| May 17, 2024 | DAVID ALTSHULER | EVP, CHIEF SCIENTIFIC OFFICER | -54.00 | $430.93 | -$23.27K | SELL | -0.21% | 25.81K | May 15 | View |
| May 03, 2024 | Sangeeta Bhatia | DIRECTOR | 534.00 | $402.95 | -$188.18K | GRANT | 13.69% | 4.43K | May 01 - May 02 | View |
| Apr 03, 2024 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -465.00 | $418.56 | -$194.63K | SELL | -5.84% | 7.50K | Apr 01 - Apr 02 | View |
| Feb 27, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $431.20 | -$1.58M | SELL | -6.16% | 55.80K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -5.47K | $428.45 | -$2.34M | SELL | -8.12% | 61.89K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -2.54K | $429.67 | -$1.09M | SELL | -13.71% | 15.97K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Stuart Arbuckle | EVP, COO | -9.75K | $428.65 | -$4.18M | SELL | -16.36% | 49.83K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $428.65 | -$733.42K | SELL | -17.68% | 7.96K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -8.21K | $428.65 | -$3.52M | SELL | -24.13% | 25.81K | Feb 23 - Feb 26 | View |
| Feb 23, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -360.00 | $421.77 | -$151.84K | SELL | -0.60% | 59.47K | Feb 21 | View |
| Feb 23, 2024 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -3.19K | $421.77 | -$1.35M | SELL | -4.52% | 67.36K | Feb 21 | View |
| Feb 23, 2024 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -1.20K | $421.77 | -$506.55K | SELL | -6.09% | 18.51K | Feb 21 | View |
| Feb 23, 2024 | Stuart Arbuckle | EVP, COO | -3.60K | $421.77 | -$1.52M | SELL | -5.70% | 59.58K | Feb 21 | View |
| Feb 23, 2024 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -3.00K | $421.77 | -$1.27M | SELL | -8.11% | 34.02K | Feb 21 | View |
| Feb 21, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -8.35K | $422.44 | -$3.53M | SELL | -12.25% | 59.83K | Feb 16 - Feb 20 | View |
| Feb 21, 2024 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -10.38K | $421.82 | -$4.38M | SELL | -12.82% | 70.55K | Feb 16 - Feb 20 | View |
| Feb 21, 2024 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -3.43K | $422.13 | -$1.45M | SELL | -14.81% | 19.71K | Feb 16 - Feb 20 | View |
| Feb 21, 2024 | Stuart Arbuckle | EVP, COO | -12.68K | $421.88 | -$5.35M | SELL | -16.71% | 63.18K | Feb 16 - Feb 20 | View |
| Feb 21, 2024 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -10.56K | $421.88 | -$4.46M | SELL | -22.20% | 37.02K | Feb 16 - Feb 20 | View |
| Feb 16, 2024 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -9.01K | $419.10 | -$3.78M | SELL | -32.95% | 18.34K | Feb 14 - Feb 15 | View |
| Feb 14, 2024 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -3.39K | $419.42 | -$1.42M | SELL | -11.04% | 27.35K | Feb 12 - Feb 13 | View |
| Feb 13, 2024 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.41K | $422.41 | -$1.02M | SELL | -3.42% | 68.18K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -5.24K | $421.20 | -$2.21M | SELL | -6.09% | 80.93K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | Jonathan Biller | EVP AND CHIEF LEGAL OFFICER | -3.33K | $420.67 | -$1.40M | SELL | -15.39% | 18.28K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | Morrow Edward Atkinson III | EVP, CHIEF TECHNICAL OPS. OFF. | -1.75K | $421.43 | -$735.40K | SELL | -7.01% | 23.14K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | Stuart Arbuckle | EVP, COO | -7.47K | $421.30 | -$3.15M | SELL | -8.97% | 75.86K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.97K | $420.99 | -$827.25K | SELL | -16.88% | 9.68K | Feb 09 - Feb 12 | View |
| Feb 13, 2024 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -5.24K | $421.24 | -$2.21M | SELL | -9.93% | 47.59K | Feb 09 - Feb 12 | View |
| Jan 10, 2024 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -6.65K | $419.07 | -$2.79M | SELL | -69.90% | 2.86K | Jan 08 | View |
| Jan 04, 2024 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $405.00 | -$1.22M | SELL | -6.42% | 43.69K | Jan 02 | View |
| Dec 19, 2023 | Reshma Kewalramani | CEO & PRESIDENT | 0.00 | $294.41 | -$3.86M | SELL-OPTIONS | 0.00% | 108.71K | Dec 15 | View |
| Dec 15, 2023 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -13.35K | $399.42 | -$5.33M | SELL | -58.40% | 9.51K | Dec 13 | View |
| Dec 15, 2023 | Reshma Kewalramani | CEO & PRESIDENT | -5.10K | $397.00 | -$2.02M | SELL | -4.48% | 108.71K | Dec 13 | View |
| Dec 15, 2023 | Stuart Arbuckle | EVP, COO | 0.00 | $293.26 | -$1.82M | SELL-OPTIONS | 0.00% | 56.70K | Dec 13 | View |
| Nov 21, 2023 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $349.88 | -$1.05M | SELL | -6.04% | 46.69K | Nov 20 | View |
| Nov 17, 2023 | Amit Sachdev | EVP CHIEF PATIENT & EXT AF OFF | -35.00 | $369.92 | -$12.95K | SELL | -0.05% | 65.38K | Nov 15 | View |
| Nov 17, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -19.00 | $369.92 | -$7.03K | SELL | -0.06% | 32.04K | Nov 15 | View |
| Nov 16, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $380.82 | -$2.15M | SELL | -16.17% | 29.30K | Nov 14 | View |
| Nov 15, 2023 | Reshma Kewalramani | CEO & PRESIDENT | -5.10K | $377.00 | -$1.92M | SELL | -4.29% | 113.81K | Nov 13 | View |
| Nov 08, 2023 | BRUCE SACHS | DIRECTOR | 0.00 | $256.27 | -$2.90M | SELL-OPTIONS | 0.00% | 40.00K | Nov 06 | View |
| Nov 02, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $355.92 | -$2.01M | SELL | -13.92% | 34.95K | Oct 31 | View |
| Oct 19, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $373.25 | -$2.11M | SELL | -12.22% | 40.60K | Oct 17 | View |
| Oct 19, 2023 | Sangeeta Bhatia | DIRECTOR | -243.00 | $375.00 | -$91.13K | SELL | -5.86% | 3.90K | Oct 17 | View |
| Oct 18, 2023 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -12.96K | $374.00 | -$4.85M | SELL | -36.18% | 22.86K | Oct 16 | View |
| Oct 11, 2023 | Sangeeta Bhatia | DIRECTOR | -242.00 | $360.00 | -$87.12K | SELL | -5.52% | 4.14K | Oct 06 | View |
| Oct 05, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $345.28 | -$1.95M | SELL | -10.89% | 46.25K | Oct 03 | View |
| Oct 03, 2023 | Jonathan Biller | EVP AND CHIEF LEGAL OFFICER | -1.02K | $348.35 | -$354.62K | SELL | -8.79% | 10.57K | Sep 29 - Oct 02 | View |
| Sep 21, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $351.00 | -$1.98M | SELL | -9.82% | 51.91K | Sep 19 | View |
| Sep 07, 2023 | Carmen Bozic | EVP AND CMO | -5.65K | $352.66 | -$1.99M | SELL | -8.94% | 57.56K | Sep 05 | View |
| Aug 25, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.50K | $355.00 | -$887.50K | SELL | -4.89% | 48.64K | Aug 23 | View |
| Aug 14, 2023 | Terrence Kearney | DIRECTOR | 0.00 | $238.77 | -$2.22M | SELL-OPTIONS | 0.00% | 6.54K | Aug 10 | View |
| Aug 14, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -5.75K | $345.79 | -$1.99M | SELL | -10.11% | 51.14K | Aug 10 | View |
| Aug 14, 2023 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -10.03K | $350.00 | -$3.51M | SELL | -13.30% | 65.38K | Aug 10 | View |
| Aug 11, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -63.00 | $345.51 | -$21.77K | SELL | -0.20% | 32.04K | Aug 09 | View |
| Aug 11, 2023 | Sangeeta Bhatia | DIRECTOR | -242.00 | $345.51 | -$83.61K | SELL | -5.23% | 4.39K | Aug 09 | View |
| Jul 18, 2023 | BRUCE SACHS | DIRECTOR | 0.00 | $242.15 | -$2.58M | SELL-OPTIONS | 0.00% | 40.00K | Jul 17 | View |
| Jul 18, 2023 | Reshma Kewalramani | CEO & PRESIDENT | -7.83K | $355.00 | -$2.78M | SELL | -6.18% | 118.91K | Jul 17 | View |
| Jun 20, 2023 | Stuart Arbuckle | EVP, COO | 0.00 | $268.26 | -$1.39M | SELL-OPTIONS | 0.00% | 56.70K | Jun 15 | View |
| Jun 01, 2023 | Stuart Arbuckle | EVP, COO | -82.00 | $329.82 | -$27.05K | SELL | -0.14% | 56.70K | May 30 | View |
| Jun 01, 2023 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -289.00 | $329.82 | -$95.32K | SELL | -4.06% | 6.84K | May 30 | View |
| May 09, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -3.27K | $350.00 | -$1.15M | SELL | -9.27% | 32.04K | May 05 - May 08 | View |
| May 09, 2023 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -2.00K | $349.25 | -$699.89K | SELL | -5.30% | 35.83K | May 05 - May 08 | View |
| May 04, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -4.40K | $350.71 | -$1.54M | SELL | -11.09% | 35.31K | May 02 - May 03 | View |
| May 04, 2023 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -10.96K | $349.98 | -$3.84M | SELL | -22.46% | 37.83K | May 02 - May 03 | View |
| May 03, 2023 | Sangeeta Bhatia | DIRECTOR | 588.00 | $348.28 | -$202.00K | GRANT | 14.55% | 4.63K | May 01 - May 02 | View |
| May 01, 2023 | Reshma Kewalramani | CEO & PRESIDENT | -3.32K | $339.08 | -$1.12M | SELL | -2.55% | 126.65K | Apr 27 | View |
| Apr 14, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -7.57K | $326.70 | -$2.47M | SELL | -16.00% | 39.71K | Apr 12 | View |
| Apr 14, 2023 | BRUCE SACHS | DIRECTOR | -1.21K | $199.44 | -$5.42M | SELL | -2.94% | 40.00K | Apr 12 - Apr 13 | View |
| Apr 06, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -522.00 | $315.81 | -$164.85K | SELL | -1.09% | 47.28K | Apr 04 | View |
| Mar 28, 2023 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -1.77K | $305.38 | -$539.91K | SELL | -3.44% | 49.61K | Mar 24 | View |
| Mar 21, 2023 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -2.00K | $296.39 | -$592.79K | SELL | -3.75% | 51.38K | Mar 17 | View |
| Mar 20, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -2.75K | $300.59 | -$825.42K | SELL | -5.28% | 49.27K | Mar 16 | View |
| Mar 14, 2023 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -4.75K | $291.98 | -$1.39M | SELL | -8.18% | 53.38K | Mar 10 - Mar 13 | View |
| Feb 28, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $288.96 | -$1.06M | SELL | -6.06% | 56.80K | Feb 24 - Feb 27 | View |
| Feb 28, 2023 | Stuart Arbuckle | EVP, COO | -9.75K | $288.27 | -$2.81M | SELL | -14.67% | 56.70K | Feb 24 - Feb 27 | View |
| Feb 28, 2023 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $288.01 | -$492.21K | SELL | -18.96% | 7.30K | Feb 24 - Feb 27 | View |
| Feb 28, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -8.21K | $288.29 | -$2.37M | SELL | -20.39% | 32.04K | Feb 24 - Feb 27 | View |
| Feb 24, 2023 | Stuart Arbuckle | EVP, COO | -2.40K | $294.33 | -$706.68K | SELL | -3.49% | 66.44K | Feb 22 | View |
| Feb 22, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -4.98K | $292.94 | -$1.46M | SELL | -7.61% | 60.47K | Feb 17 - Feb 21 | View |
| Feb 22, 2023 | Stuart Arbuckle | EVP, COO | -6.90K | $293.16 | -$2.02M | SELL | -9.11% | 68.84K | Feb 17 - Feb 21 | View |
| Feb 22, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -7.75K | $293.33 | -$2.27M | SELL | -16.15% | 40.25K | Feb 17 - Feb 21 | View |
| Feb 16, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -320.00 | $298.52 | -$95.53K | SELL | -0.49% | 65.44K | Feb 14 | View |
| Feb 16, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -2.18K | $300.39 | -$655.16K | SELL | -3.52% | 59.73K | Feb 14 | View |
| Feb 16, 2023 | Stuart Arbuckle | EVP, COO | -6.40K | $298.68 | -$1.91M | SELL | -7.79% | 75.75K | Feb 14 | View |
| Feb 16, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -6.40K | $298.70 | -$1.91M | SELL | -11.76% | 48.00K | Feb 14 | View |
| Feb 14, 2023 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -4.65K | $297.14 | -$1.38M | SELL | -6.60% | 65.77K | Feb 10 - Feb 13 | View |
| Feb 14, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -5.36K | $297.64 | -$1.59M | SELL | -7.96% | 61.91K | Feb 10 - Feb 13 | View |
| Feb 14, 2023 | Stuart Arbuckle | EVP, COO | -14.25K | $297.56 | -$4.24M | SELL | -14.78% | 82.14K | Feb 10 - Feb 13 | View |
| Feb 14, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -14.25K | $297.52 | -$4.24M | SELL | -20.76% | 54.40K | Feb 10 - Feb 13 | View |
| Feb 08, 2023 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $246.76 | -$154.48K | SELL-OPTIONS | 0.00% | 68.64K | Feb 06 | View |
| Feb 02, 2023 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -106.00 | $325.00 | -$34.45K | SELL | -0.28% | 38.00K | Jan 31 | View |
| Feb 02, 2023 | BRUCE SACHS | DIRECTOR | 0.00 | $198.57 | -$303.44K | SELL-OPTIONS | 0.00% | 41.21K | Jan 31 | View |
| Jan 31, 2023 | LLOYD CARNEY | DIRECTOR | -2.70K | $320.52 | -$865.41K | SELL | -39.42% | 4.15K | Jan 30 | View |
| Jan 31, 2023 | Yuchun Lee | DIRECTOR | 0.00 | $197.08 | -$357.09K | SELL-OPTIONS | 0.00% | 1.88K | Jan 27 | View |
| Jan 27, 2023 | Yuchun Lee | DIRECTOR | 0.00 | $194.14 | -$1.95M | SELL-OPTIONS | 0.00% | 1.88K | Jan 25 - Jan 26 | View |
| Jan 27, 2023 | Reshma Kewalramani | CEO & PRESIDENT | -10.00K | $315.05 | -$3.15M | SELL | -10.04% | 89.60K | Jan 25 | View |
| Jan 25, 2023 | Yuchun Lee | DIRECTOR | 0.00 | $192.30 | -$1.47M | SELL-OPTIONS | 0.00% | 1.88K | Jan 23 - Jan 24 | View |
| Jan 19, 2023 | Yuchun Lee | DIRECTOR | 0.00 | $192.09 | -$1.07M | SELL-OPTIONS | 0.00% | 1.88K | Jan 17 - Jan 18 | View |
| Nov 17, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -34.00 | $308.61 | -$10.49K | SELL | -0.09% | 36.08K | Nov 15 | View |
| Nov 09, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $245.28 | -$150.51K | SELL-OPTIONS | 0.00% | 36.08K | Nov 07 | View |
| Nov 03, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -1.09K | $312.78 | -$340.31K | SELL | -2.78% | 38.10K | Nov 01 - Nov 02 | View |
| Oct 26, 2022 | Sangeeta Bhatia | DIRECTOR | -621.00 | $310.00 | -$192.51K | SELL | -13.32% | 4.04K | Oct 24 | View |
| Oct 20, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -1.79K | $300.31 | -$537.86K | SELL | -4.37% | 39.19K | Oct 18 | View |
| Aug 17, 2022 | Reshma Kewalramani | CEO & PRESIDENT | -11.69K | $305.06 | -$3.57M | SELL | -10.50% | 99.60K | Aug 15 | View |
| Aug 17, 2022 | Stuart Arbuckle | EVP, COO | -15.60K | $229.75 | -$5.72M | SELL | -25.57% | 45.42K | Aug 15 | View |
| Aug 17, 2022 | Joy Liu | SVP, GENERAL COUNSEL | -3.75K | $303.90 | -$1.14M | SELL | -28.06% | 9.61K | Aug 15 | View |
| Aug 12, 2022 | Stuart Arbuckle | EVP, COO | -116.00 | $227.99 | -$44.12K | SELL | -0.19% | 61.02K | Aug 10 | View |
| Aug 12, 2022 | Joy Liu | SVP, GENERAL COUNSEL | -36.00 | $300.32 | -$10.81K | SELL | -0.27% | 13.35K | Aug 10 | View |
| Aug 10, 2022 | Sangeeta Bhatia | DIRECTOR | -621.00 | $293.03 | -$181.97K | SELL | -11.76% | 4.66K | Aug 08 | View |
| Aug 10, 2022 | Joy Liu | SVP, GENERAL COUNSEL | -946.00 | $300.00 | -$283.80K | SELL | -6.60% | 13.39K | Aug 09 | View |
| Aug 10, 2022 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -1.40K | $298.97 | -$418.56K | SELL | -2.95% | 46.09K | Aug 09 | View |
| Aug 10, 2022 | Stuart Arbuckle | EVP, COO | -3.76K | $228.12 | -$1.41M | SELL | -5.80% | 61.14K | Aug 09 | View |
| Aug 10, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $240.03 | -$136.93K | SELL-OPTIONS | 0.00% | 36.08K | Aug 08 | View |
| Aug 02, 2022 | Sangeeta Bhatia | DIRECTOR | -621.00 | $278.77 | -$173.12K | SELL | -10.52% | 5.28K | Jul 29 | View |
| Jul 27, 2022 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -71.74K | $186.22 | -$31.67M | SELL | -96.16% | 2.86K | Jul 25 | View |
| Jul 21, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -100.00 | $231.49 | -$2.06M | SELL | -0.28% | 36.08K | Jul 19 | View |
| Jun 28, 2022 | Reshma Kewalramani | CEO & PRESIDENT | -11.69K | $291.30 | -$3.41M | SELL | -9.52% | 111.15K | Jun 24 | View |
| May 18, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -45.00 | $252.83 | -$11.38K | SELL | -0.11% | 41.75K | May 16 | View |
| May 18, 2022 | Stuart Arbuckle | EVP, COO | -133.00 | $251.19 | -$33.41K | SELL | -0.20% | 64.90K | May 16 | View |
| May 18, 2022 | Joy Liu | SVP, GENERAL COUNSEL | -133.00 | $252.88 | -$33.63K | SELL | -0.92% | 14.33K | May 16 | View |
| May 06, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -36.00 | $275.09 | -$9.90K | SELL | -0.09% | 41.66K | May 04 | View |
| May 04, 2022 | Stuart Arbuckle | EVP, COO | -306.00 | $263.98 | -$80.78K | SELL | -0.47% | 64.90K | May 02 | View |
| May 04, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -320.00 | $259.16 | -$82.93K | SELL | -0.76% | 41.70K | May 02 | View |
| May 04, 2022 | Sangeeta Bhatia | DIRECTOR | -737.00 | $258.94 | -$190.84K | SELL | -11.10% | 5.90K | May 02 | View |
| May 04, 2022 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -343.00 | $258.83 | -$88.78K | SELL | -0.80% | 42.73K | May 02 | View |
| May 03, 2022 | Joy Liu | SVP, GENERAL COUNSEL | -120.00 | $275.41 | -$33.05K | SELL | -0.83% | 14.33K | Apr 29 | View |
| Apr 27, 2022 | Kristen Ambrose | SVP & CHIEF ACCOUNTING OFFICER | -327.00 | $269.55 | -$88.14K | SELL | -8.55% | 3.50K | Apr 25 | View |
| Apr 20, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $182.89 | -$405.39K | SELL-OPTIONS | 0.00% | 1.88K | Apr 18 | View |
| Apr 18, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $185.30 | -$415.04K | SELL-OPTIONS | 0.00% | 1.88K | Apr 14 | View |
| Apr 14, 2022 | JEFFREY LEIDEN | EXECUTIVE CHAIRMAN | -15.79K | $289.04 | -$4.56M | SELL | -17.47% | 74.60K | Apr 13 | View |
| Apr 14, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $182.90 | -$810.90K | SELL-OPTIONS | 0.00% | 1.88K | Apr 12 - Apr 13 | View |
| Apr 12, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $180.49 | -$791.58K | SELL-OPTIONS | 0.00% | 1.88K | Apr 08 - Apr 11 | View |
| Apr 12, 2022 | Sangeeta Bhatia | DIRECTOR | 0.00 | $202.95 | -$294.61K | SELL-OPTIONS | 0.00% | 5.19K | Apr 08 | View |
| Apr 12, 2022 | MARGARET MCGLYNN | DIRECTOR | 0.00 | $203.88 | -$763.38K | SELL-OPTIONS | 0.00% | 1.10K | Apr 08 | View |
| Apr 08, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $177.39 | -$766.80K | SELL-OPTIONS | 0.00% | 1.88K | Apr 06 - Apr 07 | View |
| Apr 08, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -561.00 | $276.18 | -$154.93K | SELL | -1.29% | 42.78K | Apr 07 | View |
| Apr 06, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -3.73K | $274.10 | -$1.02M | SELL | -7.91% | 43.34K | Apr 04 - Apr 05 | View |
| Apr 06, 2022 | Yuchun Lee | DIRECTOR | 0.00 | $175.82 | -$754.26K | SELL-OPTIONS | 0.00% | 1.88K | Apr 04 - Apr 05 | View |
| Apr 05, 2022 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -2.58K | $264.76 | -$683.60K | SELL | -5.59% | 43.62K | Apr 01 | View |
| Apr 04, 2022 | MARGARET MCGLYNN | DIRECTOR | 0.00 | $194.90 | -$673.65K | SELL-OPTIONS | 0.00% | 1.10K | Mar 31 | View |
| Mar 21, 2022 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.83K | $250.11 | -$708.57K | SELL | -5.64% | 47.36K | Mar 17 | View |
| Mar 21, 2022 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | -3.17K | $250.15 | -$793.22K | SELL | -6.42% | 46.20K | Mar 17 | View |
| Mar 21, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -2.12K | $250.06 | -$530.63K | SELL | -4.20% | 48.41K | Mar 17 | View |
| Feb 28, 2022 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -2.92K | $228.20 | -$665.22K | SELL | -5.49% | 50.19K | Feb 24 - Feb 25 | View |
| Feb 28, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -13.61K | $229.60 | -$3.12M | SELL | -27.39% | 36.08K | Feb 24 - Feb 25 | View |
| Feb 22, 2022 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -4.63K | $232.34 | -$1.08M | SELL | -8.02% | 53.10K | Feb 17 - Feb 18 | View |
| Feb 22, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -7.75K | $231.65 | -$1.80M | SELL | -13.49% | 49.69K | Feb 17 - Feb 18 | View |
| Feb 16, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -2.44K | $232.02 | -$567.06K | SELL | -4.08% | 57.44K | Feb 14 | View |
| Feb 14, 2022 | Ourania Tatsis | EVP, CHIEF REG. & QUALITY OFF. | -1.52K | $237.23 | -$360.60K | SELL | -2.57% | 57.74K | Feb 10 - Feb 11 | View |
| Feb 14, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -5.82K | $236.66 | -$1.38M | SELL | -8.85% | 59.88K | Feb 10 - Feb 11 | View |
| Feb 03, 2022 | CHARLES WAGNER JR | EVP & CHIEF FINANCIAL OFFICER | 22.64K | $250.07 | -$736.21K | GRANT | 65.09% | 57.44K | Feb 01 - Feb 02 | View |
| Feb 03, 2022 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | 22.38K | $248.51 | -$389.17K | GRANT | 68.69% | 54.95K | Feb 01 - Feb 02 | View |
| Feb 03, 2022 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | 32.11K | $168.99 | -$768.66K | SELL-OPTIONS | 95.59% | 65.70K | Feb 01 - Feb 02 | View |
| Feb 01, 2022 | MARGARET MCGLYNN | DIRECTOR | 0.00 | $184.67 | -$571.26K | SELL-OPTIONS | 0.00% | 1.10K | Jan 28 | View |
| Nov 16, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -51.00 | $187.19 | -$9.55K | SELL | -0.11% | 47.50K | Nov 15 | View |
| Nov 16, 2021 | Stuart Arbuckle | EVP, COO | -3.00 | $187.26 | -$561.78 | SELL | -0.01% | 41.24K | Nov 15 | View |
| Nov 16, 2021 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -34.00 | $187.22 | -$6.37K | SELL | -0.10% | 33.59K | Nov 15 | View |
| Aug 23, 2021 | Reshma Kewalramani | CEO & PRESIDENT | 10.00K | $195.65 | $1.96M | BUY | 15.69% | 73.75K | Aug 19 | View |
| Aug 04, 2021 | BRUCE SACHS | DIRECTOR | 15.00K | $197.91 | $2.97M | BUY | 57.23% | 41.21K | Aug 02 | View |
| Jun 04, 2021 | Sangeeta Bhatia | DIRECTOR | -559.00 | $209.69 | -$117.22K | SELL | -9.72% | 5.19K | Jun 02 | View |
| May 19, 2021 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -112.00 | $216.34 | -$24.23K | SELL | -0.33% | 34.11K | May 17 | View |
| May 19, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -45.00 | $216.35 | -$9.74K | SELL | -0.09% | 47.50K | May 17 | View |
| May 19, 2021 | Joy Liu | SVP, GENERAL COUNSEL | -112.00 | $216.34 | -$24.23K | SELL | -1.34% | 8.25K | May 17 | View |
| May 19, 2021 | Stuart Arbuckle | EVP, CHIEF COMM & OPS OFFICER | -109.00 | $216.41 | -$23.59K | SELL | -0.26% | 41.24K | May 17 | View |
| May 19, 2021 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -79.00 | $216.36 | -$17.09K | SELL | -0.23% | 33.59K | May 17 | View |
| May 05, 2021 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -1.73K | $217.89 | -$376.07K | SELL | -4.82% | 34.11K | Apr 30 - May 03 | View |
| Apr 29, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | 0.00 | $151.29 | -$503.15K | SELL-OPTIONS | 0.00% | 47.50K | Apr 27 | View |
| Apr 07, 2021 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -1.69K | $214.14 | -$361.05K | SELL | -4.49% | 35.83K | Apr 05 | View |
| Mar 08, 2021 | Joy Liu | SVP, GENERAL COUNSEL | -5.14K | $209.69 | -$1.08M | SELL | -38.38% | 8.25K | Mar 05 | View |
| Mar 02, 2021 | Paul Silva | SVP & CHIEF ACCOUNTING OFFICER | -5.00K | $211.88 | -$1.06M | SELL | -33.22% | 10.05K | Feb 26 - Mar 01 | View |
| Feb 26, 2021 | Paul Silva | SVP & CHIEF ACCOUNTING OFFICER | -1.94K | $215.29 | -$418.53K | SELL | -11.44% | 15.05K | Feb 24 - Feb 25 | View |
| Feb 26, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -6.53K | $215.29 | -$1.41M | SELL | -12.09% | 47.50K | Feb 24 - Feb 25 | View |
| Feb 26, 2021 | Michael Parini | EVP, CHIEF ADM, LEG & BD OFF | -5.44K | $215.24 | -$1.17M | SELL | -15.01% | 30.84K | Feb 24 - Feb 25 | View |
| Feb 26, 2021 | Stuart Arbuckle | EVP, CHIEF COMMERCIAL OFFICER | -6.53K | $215.33 | -$1.41M | SELL | -13.67% | 41.24K | Feb 24 - Feb 25 | View |
| Feb 26, 2021 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -5.44K | $215.24 | -$1.17M | SELL | -13.95% | 33.59K | Feb 24 - Feb 25 | View |
| Feb 19, 2021 | Paul Silva | SVP & CHIEF ACCOUNTING OFFICER | -7.04K | $211.80 | -$1.49M | SELL | -29.27% | 17.00K | Feb 17 - Feb 18 | View |
| Feb 19, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -16.88K | $211.79 | -$3.57M | SELL | -23.80% | 54.03K | Feb 17 - Feb 18 | View |
| Feb 19, 2021 | Michael Parini | EVP, CHIEF ADM, LEG & BD OFF | -14.06K | $211.79 | -$2.98M | SELL | -27.94% | 36.28K | Feb 17 - Feb 18 | View |
| Feb 19, 2021 | Stuart Arbuckle | EVP, CHIEF COMMERCIAL OFFICER | -14.06K | $211.79 | -$2.98M | SELL | -22.74% | 47.77K | Feb 17 - Feb 18 | View |
| Feb 19, 2021 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -14.06K | $211.80 | -$2.98M | SELL | -26.49% | 39.03K | Feb 17 - Feb 18 | View |
| Feb 16, 2021 | Paul Silva | SVP & CHIEF ACCOUNTING OFFICER | -1.50K | $210.57 | -$315.44K | SELL | -5.87% | 24.03K | Feb 11 | View |
| Feb 16, 2021 | Bastiano Sanna | EVP, CELL & GENETIC THERAPIES | -1.69K | $210.56 | -$355.01K | SELL | -4.16% | 38.86K | Feb 11 | View |
| Feb 16, 2021 | Amit Sachdev | EVP, CHIEF PATIENT OFFICER | -4.46K | $210.55 | -$939.07K | SELL | -5.92% | 70.91K | Feb 11 | View |
| Feb 16, 2021 | Michael Parini | EVP, CHIEF ADM, LEG & BD OFF | -4.32K | $210.56 | -$909.18K | SELL | -7.90% | 50.35K | Feb 11 | View |
| Feb 16, 2021 | Stuart Arbuckle | EVP, CHIEF COMMERCIAL OFFICER | -5.16K | $210.55 | -$1.09M | SELL | -7.70% | 61.84K | Feb 11 | View |
| Feb 16, 2021 | DAVID ALTSHULER | EVP, GLOBAL RESEARCH AND CSO | -5.28K | $210.54 | -$1.11M | SELL | -9.05% | 53.10K | Feb 11 | View |
| Feb 09, 2021 | Michael Parini | EVP, CHIEF ADM, LEG & BD OFF | 0.00 | $150.76 | -$247.97K | SELL-OPTIONS | 0.00% | 57.23K | Feb 05 | View |
| Feb 05, 2021 | Michael Parini | EVP, CHIEF ADM, LEG & BD OFF | 30.39K | $151.54 | -$52.02K | SELL-OPTIONS | 113.23% | 57.23K | Feb 03 | View |
| Feb 05, 2021 | Stuart Arbuckle | EVP, CHIEF COMMERCIAL OFFICER | 34.78K | $150.13 | -$197.69K | SELL-OPTIONS | 98.47% | 70.10K | Feb 03 | View |
| Nov 18, 2020 | Amit Sachdev | — | -42.00 | $223.53 | -$9.39K | SELL | -0.09% | 49.10K | Nov 16 | View |
| Nov 18, 2020 | Michael Parini | — | -91.00 | $223.53 | -$20.34K | SELL | -0.34% | 26.84K | Nov 16 | View |
| Nov 18, 2020 | Stuart Arbuckle | — | -7.00 | $223.64 | -$1.57K | SELL | -0.02% | 35.32K | Nov 16 | View |
| Nov 18, 2020 | DAVID ALTSHULER | — | -38.00 | $223.47 | -$8.49K | SELL | -0.13% | 28.90K | Nov 16 | View |
| Nov 12, 2020 | BRUCE SACHS | — | 15.00K | $217.36 | $3.26M | PURCHASE | 133.81% | 26.21K | Nov 10 | View |
| Nov 06, 2020 | Michael Parini | — | 0.00 | $152.13 | -$305.74K | OPTION EXERCISE | 0.00% | 26.84K | Nov 04 | View |
| Nov 05, 2020 | Stuart Arbuckle | — | 0.00 | $149.22 | -$194.75K | OPTION EXERCISE | 0.00% | 35.32K | Nov 03 | View |
| Oct 07, 2020 | Sangeeta Bhatia | — | -1.79K | $196.73 | -$1.70M | OPTION EXERCISE | -31.38% | 3.91K | Oct 05 | View |
| Aug 10, 2020 | Paul Silva | — | 0.00 | $220.28 | -$109.72K | OPTION EXERCISE | 0.00% | 15.10K | Aug 06 | View |
| Aug 10, 2020 | Michael Parini | — | 0.00 | $213.38 | -$141.41K | OPTION EXERCISE | 0.00% | 26.84K | Aug 06 | View |
| Aug 10, 2020 | Reshma Kewalramani | — | 0.00 | $225.44 | -$189.72K | OPTION EXERCISE | 0.00% | 26.63K | Aug 06 | View |
| Aug 10, 2020 | DAVID ALTSHULER | — | 0.00 | $213.38 | -$141.40K | OPTION EXERCISE | 0.00% | 28.90K | Aug 06 | View |
| Aug 05, 2020 | Amit Sachdev | — | 0.00 | $182.40 | -$372.20K | OPTION EXERCISE | 0.00% | 49.10K | Aug 03 | View |
| Aug 05, 2020 | Paul Silva | — | 0.00 | $182.41 | -$155.15K | OPTION EXERCISE | 0.00% | 15.10K | Aug 03 | View |
| Aug 05, 2020 | Michael Parini | — | 0.00 | $182.40 | -$446.81K | OPTION EXERCISE | 0.00% | 26.84K | Aug 03 | View |
| Aug 05, 2020 | Stuart Arbuckle | — | 0.00 | $182.45 | -$297.97K | OPTION EXERCISE | 0.00% | 35.32K | Aug 03 | View |
| Aug 05, 2020 | DAVID ALTSHULER | — | 0.00 | $182.38 | -$446.70K | OPTION EXERCISE | 0.00% | 28.90K | Aug 03 | View |
| Jul 15, 2020 | Paul Silva | — | 0.00 | $191.16 | -$173.50K | OPTION EXERCISE | 0.00% | 15.10K | Jul 13 | View |
| Jul 15, 2020 | Michael Parini | — | 0.00 | $191.17 | -$428.74K | OPTION EXERCISE | 0.00% | 26.84K | Jul 13 | View |
| Jul 14, 2020 | CHARLES WAGNER JR | — | -700.00 | $293.15 | -$205.21K | SELL | -4.16% | 16.13K | Jul 10 | View |
| Jul 09, 2020 | Stuart Arbuckle | — | 0.00 | $236.76 | -$352.40K | OPTION EXERCISE | 0.00% | 35.32K | Jul 07 | View |
| Jul 02, 2020 | JEFFREY LEIDEN | — | -32.79K | $286.15 | -$9.38M | SELL | -92.39% | 2.70K | Jun 30 | View |
| Jun 03, 2020 | Sangeeta Bhatia | — | 446.00 | $282.88 | -$269.30K | GRANT OR AWARD | 8.50% | 5.70K | Jun 01 - Jun 02 | View |
| May 19, 2020 | Reshma Kewalramani | — | -99.00 | $284.17 | -$28.13K | SELL | -0.37% | 26.63K | May 15 | View |
| May 19, 2020 | Ourania Tatsis | — | -120.00 | $284.00 | -$34.08K | SELL | -0.93% | 12.74K | May 15 | View |
| May 19, 2020 | Paul Silva | — | -151.00 | $284.00 | -$42.88K | SELL | -0.99% | 15.10K | May 15 | View |
| May 19, 2020 | Amit Sachdev | — | -58.00 | $284.41 | -$16.50K | SELL | -0.12% | 49.10K | May 15 | View |
| May 19, 2020 | Michael Parini | — | -68.00 | $284.40 | -$19.34K | SELL | -0.25% | 26.84K | May 15 | View |
| May 19, 2020 | Stuart Arbuckle | — | -113.00 | $283.98 | -$32.09K | SELL | -0.32% | 35.32K | May 15 | View |
| May 19, 2020 | DAVID ALTSHULER | — | -82.00 | $284.37 | -$23.32K | SELL | -0.28% | 28.90K | May 15 | View |
| May 14, 2020 | JEFFREY LEIDEN | — | -5.84K | $210.50 | -$14.58M | OPTION EXERCISE | -14.15% | 35.42K | May 12 | View |
| May 14, 2020 | DAVID ALTSHULER | — | 0.00 | $237.43 | -$130.14K | OPTION EXERCISE | 0.00% | 28.90K | May 12 | View |
| May 13, 2020 | Amit Sachdev | — | 0.00 | $207.25 | -$1.61M | OPTION EXERCISE | 0.00% | 49.10K | May 11 | View |
| May 13, 2020 | Michael Parini | — | 0.00 | $236.76 | -$128.40K | OPTION EXERCISE | 0.00% | 26.84K | May 11 | View |
| May 08, 2020 | Ourania Tatsis | — | 0.00 | $223.38 | -$95.28K | OPTION EXERCISE | 0.00% | 12.74K | May 06 | View |
| May 08, 2020 | Paul Silva | — | 0.00 | $221.06 | -$111.22K | OPTION EXERCISE | 0.00% | 15.10K | May 06 | View |
| May 08, 2020 | BRUCE SACHS | — | 0.00 | $170.17 | -$8.97M | OPTION EXERCISE | 0.00% | 11.21K | May 07 | View |
| May 08, 2020 | Amit Sachdev | — | 0.00 | $203.58 | -$95.93K | OPTION EXERCISE | 0.00% | 49.10K | May 06 | View |
| May 08, 2020 | Michael Parini | — | 0.00 | $214.10 | -$143.06K | OPTION EXERCISE | 0.00% | 26.84K | May 06 | View |
| May 08, 2020 | JEFFREY LEIDEN | — | -5.83K | $203.65 | -$13.28M | OPTION EXERCISE | -12.39% | 41.26K | May 07 | View |
| May 08, 2020 | Reshma Kewalramani | — | 0.00 | $226.26 | -$193.24K | OPTION EXERCISE | 0.00% | 26.63K | May 06 | View |
| May 08, 2020 | DAVID ALTSHULER | — | 0.00 | $214.12 | -$143.09K | OPTION EXERCISE | 0.00% | 28.90K | May 06 | View |
| May 07, 2020 | JEFFREY LEIDEN | — | -5.83K | $203.73 | -$13.30M | OPTION EXERCISE | -11.02% | 47.10K | May 05 | View |
| May 06, 2020 | Amit Sachdev | — | 0.00 | $190.74 | -$8.38M | OPTION EXERCISE | 0.00% | 49.10K | May 04 - May 05 | View |
| May 06, 2020 | Stuart Arbuckle | — | 0.00 | $173.64 | -$270.59K | OPTION EXERCISE | 0.00% | 35.32K | May 04 | View |
| May 06, 2020 | Paul Silva | — | 0.00 | $173.70 | -$141.05K | OPTION EXERCISE | 0.00% | 15.10K | May 04 | View |
| May 06, 2020 | Michael Parini | — | 0.00 | $173.70 | -$406.24K | OPTION EXERCISE | 0.00% | 26.84K | May 04 | View |
| May 06, 2020 | DAVID ALTSHULER | — | 0.00 | $173.69 | -$406.21K | OPTION EXERCISE | 0.00% | 28.90K | May 04 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
